Faculty

Institution

Unit

Venue

Zhihong Zeng

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hematopoietic Biology And Malignancy

Zhihong Zeng is currently serving as a Hematopoietic Biology And Malignancy Assistant Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Zhihong Zeng

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

leukemia hematology immunology hematological malignancies pharmacology oncology medicinal research tumor biology cancer research cell biology oncogenes myeloid neoplasia therapeutic targets molecular biology stem cells cancer cells cancer immunotherapy stem cell research enzyme inhibition malignant blood disorders cell death cancer biology cancer treatment apoptosis cellular therapy bone marrow transplantation tumor microenvironment cell transplantation novel therapies anti-cancer agents stem-cell therapy acute myeloid leukemia pharmacotherapy tumor suppressors blood cells cell therapy cancer discovery hemostasis molecular cancer cancer care inhibitory activity aml cells clinical transplantation remedial action cellular immune responses stem cell transplantation cancer management cancer genetics tumor targeting chemoprevention strategies signaling pathways cytokines myeloid malignancies acute myelogenous leukemia proteome research biological microenvironments therapeutic efficacy catalyst activation disease progression oncogenic agent protein expression stem cell mobilization bone marrow microenvironment cytogenetics drug targeting leukemia microenvironment aml microenvironment leukemia therapy refractory hematologic malignancies mammalian target rapamycin inhibitor everolimus acute leukemias stroma-mediated chemoresistance therapeutic targeting microenvironmental interactions antileukemia activity

Notable Scholarly Works

Notable Federal Grants

Collaborators

Bh3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism. Cell Death Discovery (2025)

Kapil SaxenaShao-Hsi HungEsther RyuShailbala SinghQi Zhang TatarataZhihong ZengZhe WangMarina Y. KonoplevaCassian Yee

cancer immunotherapycell signalingimmunologycell deathhematological malignancieshematologycellular regulatory mechanismmitochondrial apoptotic mechanismcellular immune responsesacute myeloid leukemiamolecular biologysystems biologyleukemiaoncology

Menin Inhibitor Ds-1594B Drives Differentiation and Induces Synergistic Lethality in Combination With Venetoclax in Acute Myeloid Leukemia Cells With Rearranged Mixedlineage Leukemia and Mutated Nucleophosmin-1. Haematologica (2025)

oncogenesmixed-phenotype acute leukemiacell biologyhematological malignancieshematologytherapeutic targetsleukemiamyeloid neoplasia

Pparγ-Induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in Aml. Blood Neoplasia (2025)

Kotoko YamataniTatsuro WatanabeKaori SaitoAbdullah KhasawnehAbhishek MaitiZhihong ZengKala HayesShinya KimuraCourtney D. DiNardoXiaoping SuShuko NojiriYasushi OkazakiMichael AndreeffMarina KonoplevaYoko Tabe

drug resistancepharmacologypparg-induced upregulation

Rapid Clonal Selection Within Early Hematopoietic Cell Compartments Presages the Outcome of Ivosidenib Combination Therapy. Blood (2025)

ivosidenib combination therapypathologyrapid clonal selectionhaematopoiesisimmunologyblood cellshematologybone marrow transplantationcellular therapymyelopoiesismedicineleukemia

Supplementary Tables and Figures From a Phase Ib/II Study of Ivosidenib With Venetoclax ± Azacitidine in I Idh1 /I -Mutated Myeloid Malignancies. (2025)

future medicinal chemistryoncogenespathologyhematological malignancieshematologymyeloid malignanciesdrug resistancecancer researchoncogenic agentmedicinepharmacologytherapeutic targetsvenetoclax ± azacitidinepharmacotherapyleukemiaoncologymyeloid neoplasiasupplementary tables

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies is Established Early During Treatment in Idh1 -Mutated Myeloid Malignancies. Blood (2024)

Sven TurkaljBilyana StoilovaAngus J GroomFelix A RadtkeRabea MecklenbrauckNiels Asger JakobsenCurtis A LachowiezMarlen MetznerBatchimeg UsukhbayarMirian Angulo SalazarZhihong ZengSanam LoghaviJennifer Marvin-PeekVerena KörberFarhad RavandiGhayas C. IssaTapan M. KadiaVasiliki SymeonidouAnne De GrootHagop M. KantarjianKoichi TakahashiMarina KonoplevaCourtney D. DiNardoParesh Vyas

resistance mutation (virology)clonal basisimmunologypharmacologycombination therapiesmyeloid malignanciesmyeloid neoplasiacancer immunotherapyhematologycancer researchcancer cellscancer treatmentpharmacotherapymalignant blood disordersoncogenesmedicinal researchdrug resistancehematological malignanciesmedicineleukemiaoncology

Decitabine, Venetoclax, and Ponatinib for Advanced Phase Chronic Myeloid Leukaemia and Philadelphia Chromosome-Positive Acute Myeloid Leukaemia: A Single-Arm, Single-Centre Phase 2 Trial. The Lancet Haematology (2024)

Nicholas J ShortDaniel NguyenElias JabbourJayastu SenapatiZhihong ZengGhayas C IssaHussein AbbasCedric NasnasWei QiaoXuelin HuangGautam BorthakurKelly ChienFadi G HaddadNaveen PemmarajuOmer S KarrarDanielle NguyenMarina KonoplevaHagop KantarjianFarhad Ravandi

cytogeneticsbiostatisticsneurologyrheumatologytranslational medicinemedicinal researchhematological malignancieshematologypediatric urologyjama oncologydisease assessmenttherapeutic targetsurologyleukemialaboratory medicineclinical rheumatologymyeloid neoplasiadisease physiology

Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus Rna Signaling in Aml Cells and Induces T Cell Activation. Blood (2024)

Kotoko YamataniKaori SaitoAbhishek MaitiAbdullah KhasawnehFaith Jessica ParanTastuya SuzukiToru OkamotoKala HayesZhihong ZengCourtney D. DiNardoMichael AndreeffMarina KonoplevaYoko Tabe

decitabine-venetoclax treatmentendogenous retrovirus rnavirologycell activationimmunologycell biologymedicinal researchimmunotherapyantiviral researchimmune responsescellular immune responsespharmacologyaml cellsmedical virologygeneral virologyvirus research

Dual-Targeting Cd33/Cd123 Nanobody T-Cell Engager With Potent Anti-Aml Activity and Good Safety Profile. Blood Advances (2024)

Zhihong ZengAnnelies RoobrouckGeert DeschampsHelene BonnevauxStephane GuerifVeronique De BrabandereCéline AmaraEline DejonckheereAngela Virone-OddosMarielle ChironMarina KonoplevaMelissa Dullaers

potent anti-aml activitycell therapyt-regulatory cellnanomedicineimmunologynanotechnologymedicinal researchimmunotherapycellular therapybiomedical engineeringimmune responsescellular immune responsesgood safety profiletherapeutic targetsnanoparticle researchtherapeutic nanomaterialsbiomolecular engineering

Supplementary Protocol From a Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in Idh1-Mutated Myeloid Malignancies. (2024)

Curtis A. LachowiezSanam LoghaviZhihong ZengTomoyuki TanakaYi June KimHidetaka UryuSven TurkaljNiels Asger JakobsenMarlise R. LuskinDzifa Y. DuoseRebecca S S. TidwellNicholas J. ShortGautam BorthakurTapan M. KadiaLucia MasarovaGeorge D. TippettPrithviraj BoseElias J. JabbourFarhad RavandiNaval G. DaverGuillermo Garcia-ManeroHagop KantarjianJacqueline S. GarciaParesh VyasKoichi TakahashiMarina KonoplevaCourtney D. DiNardo

malignant blood disorderscancer immunotherapyimmunologymedicinal researchhematological malignancieshematologyintermediate hostdrug resistancemedicinepharmacologysupplementary protocolimmune checkpoint inhibitorsoncologymyeloid neoplasia

1
2
3
4
5
11
10 / page

Zhihong Zeng

Assistant Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Hematopoietic Biology And Malignancy

Zhihong Zeng is currently serving as a Hematopoietic Biology And Malignancy Assistant Professor at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Zhihong Zeng

The University of Texas MD Anderson Cancer Center

Assistant Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Bh3 Mimetics Augment Cytotoxic T Cell Killing of Acute Myeloid Leukemia via Mitochondrial Apoptotic Mechanism. Cell Death Discovery (2025)

Kapil SaxenaShao-Hsi HungEsther RyuShailbala SinghQi Zhang TatarataZhihong ZengZhe WangMarina Y. KonoplevaCassian Yee

oncogenesmixed-phenotype acute leukemiacell biologyhematological malignancieshematologytherapeutic targetsleukemiamyeloid neoplasia

Pparγ-Induced Upregulation of Fatty Acid Metabolism Confers Resistance to Venetoclax and Decitabine Therapy in Aml. Blood Neoplasia (2025)

drug resistancepharmacologypparg-induced upregulation

Rapid Clonal Selection Within Early Hematopoietic Cell Compartments Presages the Outcome of Ivosidenib Combination Therapy. Blood (2025)

ivosidenib combination therapypathologyrapid clonal selectionhaematopoiesisimmunologyblood cellshematologybone marrow transplantationcellular therapymyelopoiesismedicineleukemia

Supplementary Tables and Figures From a Phase Ib/II Study of Ivosidenib With Venetoclax ± Azacitidine in I Idh1 /I -Mutated Myeloid Malignancies. (2025)

Clonal Basis of Resistance and Response to Ivosidenib Combination Therapies is Established Early During Treatment in Idh1 -Mutated Myeloid Malignancies. Blood (2024)

Decitabine-Venetoclax Treatment Reactivates Endogenous Retrovirus Rna Signaling in Aml Cells and Induces T Cell Activation. Blood (2024)

Kotoko YamataniKaori SaitoAbhishek MaitiAbdullah KhasawnehFaith Jessica ParanTastuya SuzukiToru OkamotoKala HayesZhihong ZengCourtney D. DiNardoMichael AndreeffMarina KonoplevaYoko Tabe

Dual-Targeting Cd33/Cd123 Nanobody T-Cell Engager With Potent Anti-Aml Activity and Good Safety Profile. Blood Advances (2024)

Zhihong ZengAnnelies RoobrouckGeert DeschampsHelene BonnevauxStephane GuerifVeronique De BrabandereCéline AmaraEline DejonckheereAngela Virone-OddosMarielle ChironMarina KonoplevaMelissa Dullaers

Supplementary Protocol From a Phase Ib/II Study of Ivosidenib With Venetoclax +/- Azacitidine in Idh1-Mutated Myeloid Malignancies. (2024)

1
2
3
4
5
11
10 / page